Excitement Over MS Stem Cell Transplant 'Game Changer' Data
Executive Summary
An international trial has demonstrated that HSCT was more effective than standard drugs for people with highly active relapsing-remitting multiple sclerosis. Also a one-off transplant compared to lifelong therapy has considerable cost-saving implications.
You may also be interested in...
Zymeworks Cuts C-Suite In Half At Crunch Time For Pipeline
New Zymeworks CEO Ken Galbraith is laying off at least 25% of the company's staff, including 50% of the senior management team, as the firm looks to advance pivotal trials of its HER2-targeted bispecific antibody zanidatamab.
Big Year For UCB As Bimzelx Awaits US Green Light
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.
UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.